Abbott Laboratories
ABT
$113.68
$0.070.06%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -80.76% | -0.12% | 36.64% | 8.16% | 478.98% |
| Total Depreciation and Amortization | -1.86% | -1.25% | -3.48% | -6.09% | -0.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -69.98% | 2.56% | 0.71% | -4.93% | 147.08% |
| Change in Net Operating Assets | 107.33% | 64.54% | -126.04% | 27.20% | -2,084.91% |
| Cash from Operations | 15.59% | 3.03% | 4.44% | 38.24% | -5.60% |
| Capital Expenditure | 4.31% | 10.79% | 5.82% | -21.61% | 4.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -39.73% | 347.37% | -163.29% | 151.85% | -111.59% |
| Cash from Investing | -5.43% | 23.06% | -28.48% | -10.59% | -5.10% |
| Total Debt Issued | 100.00% | -100.00% | -99.10% | -- | -95.45% |
| Total Debt Repaid | 88.27% | -1,273.81% | 72.13% | -716.54% | 36.11% |
| Issuance of Common Stock | -80.00% | -25.00% | 169.23% | 114.18% | -26.47% |
| Repurchase of Common Stock | 4.13% | 59.39% | -100.00% | -23.89% | -21.62% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.52% | -7.40% | -7.08% | -7.21% | -7.88% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 24.93% | -11.68% | -38.69% | -74.74% | 9.31% |
| Foreign Exchange rate Adjustments | 107.23% | -127.78% | 492.31% | 166.67% | -432.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,643.10% | -1.93% | -40.40% | -77.12% | -68.98% |